Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or OpenAthens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Successful Treatment of Autoimmune Urticaria with Low-Dose Prednisolone Therapy Administered for a Few Months: A Case Series of 42 Patients

Vas K.a · Altmayer A.a · Mihályi L.a · Garaczi E.a · Kinyó Á.c · Jakobicz E.a · Husz S.a · Kemény L.a, b · Bata-Csörgő Z.a, b

Author affiliations

aDepartment of Dermatology and Allergology, and bMTA-SZTE Dermatological Research Group, University of Szeged, Szeged, and cDepartment of Dermatology, Venereology and Oncodermatology, University of Pécs, Pécs, Hungary

Related Articles for ""

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: June 07, 2017
Accepted: September 25, 2017
Published online: January 17, 2018

Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 1

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: https://www.karger.com/DRM

Abstract

Background: Chronic spontaneous urticaria (CSU) is defined as symptoms of urticaria persisting for 6 weeks or more without obvious cause. Autologous serum skin test (ASST) positivity in patients with CSU is considered to be associated with autoimmune urticaria (AIU). Methods: In this retrospective study we retrieved the medical records of 1,073 urticaria patients seen at the Department of Dermatology and Allergology of Szeged University between January 2005 and February 2014. Forty-two patients (36 female and 6 male) met the study criteria by having CSU and giving positive results in the ASST. Our aim was to assess the clinical efficacy and safety of low-dose oral prednisolone therapy administered to patients with antihistamine-refractory ASST-positive CSU for a few months. Patients were given an initial dose (40 mg/day) of prednisolone until the complete resolution of the symptoms, usually 7-10 days, and then the dose was gradually decreased, as in other autoimmune diseases. Results: Prednisolone therapy lasted for an average of 3.6 months and a complete long-lasting response was achieved in 35 of 42 AIU patients (83.3%). The follow-up period was at least 36 months (3 years) for each AIU patient; the longest follow-up time was 139 months (11.5 years). None of the patients reported any considerable side effects. Conclusion: Based on our results, we suggest that the use of this treatment could be an alternative for the treatment of AIU. Our present results also highlight the need for other therapies in a small percentage of AIU patients. Our results suggest that AIU represents a transient autoimmunity that can be successfully treated with low-dose steroid therapy administered for a few months.

© 2018 S. Karger AG, Basel


References

  1. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, Church MK, Ensina LF, Gimenez-Arnau A, Godse K, Goncalo M, Grattan C, Hebert J, Hide M, Kaplan A, Kapp A, Abdul Latiff AH, Mathelier-Fusade P, Metz M, Nast A, Saini SS, Sanchez-Borges M, Schmid-Grendelmeier P, Simons FE, Staubach P, Sussman G, Toubi E, Vena GA, Wedi B, Zhu XJ, Maurer M: The EAACI/GA2 LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014;69:868-887.
  2. Kaplan AP: Urticaria and angioedema; in Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, Busse WW (eds): Allergy: Principles and Practice. St. Louis/Baltimore, Mosby, 1998, pp 1104-1122.
  3. Gruber BL, Baeza ML, Marchese MJ, Agnello V, Kaplan AP: Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 1988;90:213-217.
  4. Horn MP, Gerster T, Ochensberger B, Derer T, Kricek F, Jouvin MH, Kinet JP, Tschernig T, Vogel M, Stadler BM, Miescher SM: Human anti-FcƐRIα autoantibodies isolated from healthy donors cross-react with tetanus toxoid. Eur J Immunol 1999;29:1139-1148.
  5. Niimi N, Francis DM, Kermani F, O'Donnell BF, Hide M, Kobza-Black A, Winkelmann RK, Greaves MW, Barr RM: Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol 1996;106:1001-1006.
  6. Fiebiger E, Hammerschmid F, Stingl G, Maurer D: Anti-FcƐRIα autoantibodies in autoimmune-mediated disorders. Identification of a structure-function relationship. J Clin Invest 1998;101:243-251.
  7. Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW: Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993;328:1599-1604.
  8. Grattan CE, Wallington TB, Warin RP, Kennedy CT, Bradfield JW: A serological mediator in chronic idiopathic urticaria - a clinical, immunological and histological evaluation. Br J Dermatol 1986;114:583-590.
  9. Sabroe RA, Grattan CE, Francis DM, Barr RM, Kobza BA, Greaves MW: The autologous serum skin test: a screening test for autoantibodies in chronic idiopathic urticaria. Br J Dermatol 1999;140:446-452.
  10. Konstantinou GN, Asero R, Maurer M, Sabroe RA, Schmid-Grendelmeier P, Grattan CE: EAACI/GA2LEN task force consensus report: the autologous serum skin test in urticaria. Allergy 2009;64:1256-1268.
  11. Kaplan AP: Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004;114:465-474.
  12. Kaplan AP: Clinical practice. Chronic urticaria and angioedema. N Engl J Med 2002;346:175-179.
  13. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, Brown JP, Cohen A, Kim H: A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 2013;9:30.
  14. Lapolla W, Desai N, English JC 3rd: Clinical utility of testing for autoimmunity in chronic idiopathic urticaria. J Am Acad Dermatol 2012;66:e83-e88.
  15. Gyimesi E, Sipka S, Danko K, Kiss E, Hidvegi B, Gal M, Hunyadi J, Irinyi B, Szegedi A: Basophil CD63 expression assay on highly sensitized atopic donor leucocytes - a useful method in chronic autoimmune urticaria. Br J Dermatol 2004;151:388-396.
  16. Szegedi A, Irinyi B, Gal M, Hunyadi J, Danko K, Kiss E, Sipka S, Szegedi G, Gyimesi E: Significant correlation between the CD63 assay and the histamine release assay in chronic urticaria. Br J Dermatol 2006;155:67-75.
  17. Frezzolini A, Provini A, Teofoli P, Pomponi D, De Pita O: Serum-induced basophil CD63 expression by means of a tricolour flow cytometric method for the in vitro diagnosis of chronic urticaria. Allergy 2006;61:1071-1077.
  18. Lee MF, Lin TM, Liu SW, Chen YH: A rapid method of detecting autoantibody against FcƐRIα for chronic spontaneous urticaria. PLoS One 2014;9:e109565.
  19. Irinyi B, Szeles G, Gyimesi E, Tumpek J, Heredi E, Dimitrios G, Adany R, Hunyadi J, Szegedi A: Clinical and laboratory examinations in the subgroups of chronic urticaria. Int Arch Allergy Immunol 2007;144:217-225.
  20. Husz S, Mihalyi L, Kemeny L: Diagnostic value of autologous serum skin test in autoimmune urticaria. J Eur Acad Dermatol Venereol 2008;22:1023-1024.
  21. Irinyi B, Gyimesi E, Garaczi E, Bata ZS, Kemeny L, Zeher M, Remenyik E, Szegedi A: Extended diagnostic value of autologous serum skin test and basophil CD63 expression assay in chronic urticaria. Br J Dermatol 2013;168:656-658.
  22. Hajdu K, Irinyi B, Gyimesi E, Kapitany A, Dajnoki Z, Bata-Csorgo Z, Kinyo A, Kiss F, Gaspar K, Szegedi A: A simple, combined test can improve the diagnosis of autoimmune urticaria. Br J Dermatol 2017;177:864-866.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: June 07, 2017
Accepted: September 25, 2017
Published online: January 17, 2018

Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 1

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: https://www.karger.com/DRM


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.